Saluda Medical Completes $100 Million Financing Round

Saluda Medical, a leading innovator in neuromodulation therapies, has successfully completed a $100 million financing round to advance the development and commercialization of its groundbreaking medical devices. The new funding will enable the company to further expand its product offerings, scale its operations, and accelerate the global reach of its transformative solutions in the treatment of chronic pain and other neurological conditions.

The financing round was supported by a mix of existing investors and new strategic partners, underscoring confidence in Saluda Medical’s innovative approach to neuromodulation. Saluda’s proprietary closed-loop spinal cord stimulation technology has shown significant promise in providing more precise, personalized pain relief for patients with chronic pain conditions. The funding will primarily be used to support ongoing clinical trials, regulatory approvals, and commercialization efforts for its devices, which aim to improve patients’ quality of life while reducing the need for opioids and other pain management interventions.

“This financing round is a significant milestone for Saluda Medical and will allow us to continue developing and bringing to market our advanced neuromodulation solutions that have the potential to transform the treatment of chronic pain,” said John Parker, CEO of Saluda Medical. “We are excited to move forward with our mission to provide better, more effective treatments to patients and to be a leader in the evolving field of neuromodulation.”

The funds will also support the company’s plans to broaden its commercial footprint, as well as further enhance its closed-loop spinal cord stimulation technology, which delivers real-time adjustments based on patients’ physiological responses. This innovation is designed to provide more targeted pain relief, minimizing side effects and maximizing patient outcomes.

With chronic pain affecting millions of individuals worldwide, Saluda Medical’s advancements in neuromodulation offer a promising alternative to traditional treatments. The successful completion of this $100 million financing round positions Saluda Medical for continued growth as it seeks to make a meaningful impact in the rapidly evolving field of medical technology.